Allogene completes Shanghai facility to manufacture CAR-T products

Last month, as cell therapy player Allogene launched a study for its candidate targeting large B-cell lymphoma, the company put the finishing touches on a new CAR-T manufacturing facility in Shanghai.

In an email to Endpoints News, Allogene said the process from design to completion took the company just under...

Click to view original post